# Cochrane Library

# Stallmach 2022 (Continued)

Trusted evidence. Informed decisions. Better health.

# Cochrane Database of Systematic Reviews

# Interventions

|Arm|Details|n|
|---|---|---|
|Experimental arm|Multidonor FMFT 5 capsules orally twice daily, 5 days per week for weeks 1–12|58|
|Control arm|Placebo 5 capsules orally twice daily, 5 days per week for weeks 1–12| |

# Outcomes

# Primary outcome

- Clinical remission (Mayo score ≤ 2, without any subscore > 1; participants unavailable at week 12 follow-up will be considered as non-responders) at week 12 after first FMT or FMFT

# Secondary outcomes

- Steroid-free clinical remission at week 12
- Clinical response (decrease in Mayo score by 3 points with decrease in bleeding subscore by 1, or Total Mayo score 0–1) at week 12
- Quality of life (IBDQ) at weeks 0, 4, 8, 12, 24, 36, and 52
- Adverse events
- Fecal calprotectin and histologic remission (based on Geboes Histologic Scores and Nancy Histological Index) at week 12
- Microbiome/virome profiling

# Starting date

October 2021

# Contact information

Professor Andreas Stallmach

Tel: +49-3641-9 ext 324401; email: andreas.stallmach@med.uni-jena.de

# Notes

UMIN000033127

# Study name

Multicenter randomized controlled trial to study the efficacy of multidonor fecal microbiota transplantation for Crohn's disease

# Methods

Multicenter RCT conducted in Japan

# Participants

# Inclusion criteria

- People age 12 ≤ to < 80 years
- Active CD (CDAI score ≥ 150)

# Exclusion criteria

- Past history of allergy to drugs used in study
- Possibility of pregnancy
- Complications such as fistulas and perforation, except anal fistulas

# Interventions

# Experimental arm

- FMT

# Control arm

- Normal saline administration

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.